Orange Family Secures China's First Respiratory Specialty Digital Software Approvals, Pioneering Digital Therapeutics Innovation

Recently, Orange Family Technology (TIANJIN) Co., Ltd. (hereinafter referred to as “Orange Family”), a leading digital health enterprise in the field of chronic respiratory diseases in China, has frequently announced good news. According to public information,Orange Family’s independently developed “Pulmonary Function Data Transmission and Processing Software” and “Sleep Respiratory Data Transmission and Processing Software” have both obtained medical device registration certificates from the National Medical Products Administration (NMPA).

In recent years, Orange Family has achieved a series of breakthroughs in its business development:

With frequent breakthroughs in business development, what sets Orange Family apart? Its core competitive advantages lie in the product capabilities, data accumulation, and industry resources cultivated through years of dedicated engagement in clinical respiratory care services.

Since its founding in 2014, Orange Family has made steady and solid progress: participating in national-level projects led by academicians, developing core patented products through independent R&D, diversifying its business pipeline, extending services to over 2,000 grassroots medical institutions, serving 662,000 patient visits, and establishing an omni-channel data interaction system. Orange Family strives to innovate new technologies and applications that break through the limitations of traditional pharmacotherapy, helping patients improve treatment outcomes while reducing medical costs. By promoting value-based healthcare and supporting health insurance cost containment, Orange Family aims to set a benchmark for value-based care in the specialty of chronic respiratory diseases.

China has the world's largest population of patients with chronic diseases, with the number of individuals suffering from or at risk of chronic conditions approaching 500 million. In 2020, healthcare expenditure on chronic disease management in China amounted to approximately RMB 4.1 trillion.

Furthermore, with the release of the "Healthy China 2030" strategy, public health has been elevated to a national strategic priority, making the prevention and control of chronic diseases a central focus of the Healthy China initiative. Chronic respiratory diseases, represented by chronic obstructive pulmonary disease (COPD), asthma, and obstructive sleep apnea syndrome (OSAS), are among the four major categories of chronic diseases defined by the World Health Organization (WHO). With mortality rates ranking third among all causes of death, chronic respiratory diseases have imposed a significant burden of major diseases and loss of life value on the Chinese population.

In addition,The incidence and disease burden of chronic respiratory diseases are now comparable to those of other chronic conditions such as hypertension, diabetes, and hyperlipidemia; however, disease awareness and patient education levels fall far short of the widespread reach achieved for the “three highs” (hypertension, hyperglycemia, and hyperlipidemia).

Therefore,Raising public awareness, improving treatment adherence, therapeutic efficacy, and standardized management rates for chronic respiratory diseases, as well as reducing the incidence of acute exacerbations and mortality, has become the driving force behind Orange Family’s entrepreneurial innovation.

To date, Orange Family has established a comprehensive R&D and operational system for specialized digital medical products. The recent approval of this specialized digital health software will enable the creation of distinctive digital services tailored to sleep-disordered breathing and chronic airway diseases.

Image provided by Orange Family

Currently, the development of respiratory medicine has gradually shifted from infectious disease prevention and control to the discipline of pulmonary rehabilitation.For the treatment and management of specialized single-disease conditions, providing digital whole-course intervention solutions represents the direction of industrial transformation.

Only by implementing digital, multi-modal, and adaptive medical management across the entire disease course—including early screening, clinical diagnosis, standardized treatment, emergency warning, severe case prevention, long-term prescription management, home monitoring, and chronic disease rehabilitation—can a productized closed-loop specialty solution be achieved.

Development History of the Respiratory Medicine Department (Image provided by Orange Family)

Leveraging next-generation digital technologies such as evidence-based medicine-specialized digital systems, artificial intelligence, the Internet of Things, and healthcare big data, Orange Family continuously expands the boundaries of physicians’ clinical capabilities, empowers the entire diagnosis and treatment process, and gradually establishes a comprehensive digital network connecting doctors and patients to achieve whole-course management throughout the patient’s entire lifecycle.

Additionally,Orange Family has also independently developed a software system that has obtained clinical access approval, building a dynamic, interactive, and easily communicable information platform. It integrates collected data, transforming it into meaningful, actionable, and physician-friendly intelligent information, which is then fully utilized within specific application contexts to provide patients with corresponding guidance based on the information they receive.

After years of dedicated efforts, Orange Family has established and refined its innovative presence in respiratory specialties, including chronic obstructive pulmonary disease (COPD) and sleep-disordered breathing.

VCBeat learned that,The “Happy Breathing” project, led by Academician Wang Chen, has seen the participation of Orange Family since its Phase I project in 2017.

To date, the “Happy Breathing” project has completed three phases, with Orange Family Technology (TIANJIN) Co., Ltd. (“Orange Family”) participating throughout the entire process. The project has covered 28 pilot areas, including Baiyin in Gansu, Zunyi in Guizhou, Ankang in Shaanxi, Cangzhou in Hebei, Weifang in Shandong, Zhoukou in Henan, Chifeng in Inner Mongolia, Chaoyang in Beijing, Yinchuan in Ningxia, Datong in Shanxi, Xiangtan and Huaihua in Hunan, Hulunbuir in Inner Mongolia, Daqing in Heilongjiang, Tonghua in Jilin, Jinzhou in Liaoning, Heping District in Tianjin, Huangshan in Anhui, Huzhou in Zhejiang, Luoyang in Henan, Jiulongpo District in Chongqing, Hengyang in Hunan, Kunming in Yunnan, Wuhan in Hubei, Guilin in Guangxi, Deyang in Sichuan, Ganzhou in Jiangxi, and Yangzhou in Jiangsu. It is expected that nine additional regions will be added in the second half of 2021, extending coverage to 105.35 million people across 31 provinces, municipalities, and autonomous regions nationwide, with Orange Family continuing its ongoing involvement.

Through Orange Family’s “Integrated Digital Healthcare Solution for COPD,” the “Happy Breathing” project has enabled a transition in medical care from the traditional geography-based model to a digital healthcare model, leveraging portable pulmonary function devices to reach grassroots areas heavily affected by the disease and rapidly conduct screening.To date, Orange Family’s portable pulmonary function devices have screened 153,000 sets of pulmonary function data from 590 medical institutions across 29 regions.

Specifically, Orange Family has integrated its pulmonary function analysis and management system with China’s tiered diagnosis and treatment system for chronic obstructive pulmonary disease (COPD), establishing seamless data pathways for patient records, report analysis, and patient management. This integration provides robust data support for early screening, therapeutic management, and whole-course tracking of COPD patients at the primary care level, thereby enabling long-term follow-up and comprehensive data management for individuals with COPD.

And,Orange Family’s self-developed “Pulmonary Function Data Transmission and Processing Software” has obtained regulatory approval, rapidly gaining market recognition; orders for this year are projected to increase by more than fivefold compared with 2020.

Schematic Diagram of Orange Family’s Product Coverage (Image provided by Orange Family)

It is reported that,Orange Family initially entered the field of chronic respiratory diseases by focusing on the monitoring and treatment of 'snoring disorders', dedicating itself to disease monitoring and rehabilitation management for chronic respiratory conditions.

To facilitate early screening, diagnosis, and treatment of sleep apnea, Orange Family provides patients with comprehensive digital sleep-respiratory health management services. Integrated with its independently developed portable sleep monitoring devices, this solution enables continuous, overnight monitoring of patients’ respiratory status during sleep.

Furthermore, while guiding patients in dietary control, providing timed exercise reminders, and monitoring the real-time efficacy of nighttime treatment regimens, the system also enables AI-driven report analysis. It generates visual trend analyses, facilitates family-centered management, and provides intelligent assessments of therapeutic outcomes. This not only allows patients to easily interpret their data through intuitive charts but also empowers physicians and family members to remotely guide patients in self-management of their condition.

To date, Orange Family’s hardware and software system for sleep monitoring and screening has accumulated data from 164,311 patients, with market coverage spanning 16 provinces and municipalities. The recent regulatory approval of Orange Family’s independently developed “Sleep Apnea Transmission and Processing Software” will further enhance its existing distribution network, extending reach to more end-market institutions such as hospitals, dental clinics, and health examination centers.

Currently, Orange Family is collaborating with China-Japan Friendship Hospital to develop a digital therapeutic solution for medication management and efficacy assessment in patients with chronic obstructive pulmonary disease (COPD). This digital therapy can effectively enhance patient adherence and treatment effectiveness.

“Doctors and patients see not just data in this system, but solutions ‘born from data,’” Orange Family revealed to VCBeat.

In the healthcare industry, “people” are both the solvers of problems and the problems themselves. By leveraging technological approaches such as “quantification, connectivity, and intelligence,” Orange Family’s digital therapeutics for chronic respiratory diseases decouple physicians’ challenges from those of patients, encouraging active participation from both parties. Together, they collect information, ensure accurate diagnosis, appropriate medication, prognosis assessment, and long-term follow-up, thereby exploring a path toward value-based medicine that balances inclusivity, low cost, and high quality.

Moreover,By adopting a “medical-engineering integration” approach, Orange Family has also engaged in deep collaboration with clinical practitioners to jointly build a structured, visualized, and intelligent data interaction system. This enables patients to participate in their own health management in a more interpretable manner, echoing Shakespeare’s words in Macbeth: “The patient must needs be his own nurse.”

Future,Orange Family is committed to becoming a leading digital health provider in the field of chronic respiratory diseases in China. By innovating new technologies and applications that break through the limitations of traditional pharmacological treatments, we aim to improve therapeutic outcomes for patients, reduce medical costs, and establish a model of value-based care specialized in chronic respiratory conditions.